Company Focus
Sun Pharmaceuticals
Latest Sun Pharmaceuticals News
Biotechnology
India’s Sun Pharma has been blocked in its efforts to launch its JAK inhibitor Leqselvi (deuruxolitinib) in the USA. 6 November 2024
Related News
Insights
Company Spotlight
A clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies for the treatment of cancer and infectious
diseases
Latest News & Features of interest to Sun Pharmaceuticals
Expert View
In an Expert View column, Bruce Leuchter, chief executive of Neurvati Neurosciences, a Blackstone Life Sciences portfolio company, outlines the importance of increased investment in research and development and innovative business models, to bring more therapies for neurological disorders to patients. 17 May 2024
Pharmaceutical
At its meeting this week the European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) reviewed medicines regarding their safety. 17 May 2024
Biotechnology
A well-financed US start-up has in-licensed three obesity drug candidates from Chinese drugmaker Jiangsu Hengrui Pharmaceuticals. 17 May 2024
Biotechnology
Johnson & Johnson has entered into a definitive agreement to acquire Proteologix, the US healthcare giant revealed yesterday. 17 May 2024
Pharmaceutical
German drugmaker Bayer will present positive results from the OASIS 1 and 2 studies at the annual meeting of the American College of Obstetricians and Gynecologists (ACOG) today. 17 May 2024
Pharmaceutical
Boston, USA-based start-up Monte Rosa Therapeutics intends to raise around $100 million through a public share offering. 17 May 2024
Pharmaceutical
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of incretin mimetic medicines for the treatment of type 2 diabetes and obesity, and an ever more active sector for the pharma industry. 17 May 2024
Biotechnology
American biopharma company Biogen is to pull the plug on two antisense oligonucleotide (ASO) programs. 17 May 2024
Biotechnology
Positive high-level results have been presented from the SUPERNOVA Phase III COVID-19 pre-exposure prophylaxis (prevention) trial of AstraZeneca’s sipavibart. 16 May 2024
Pharmaceutical
Jo Latimer, head of neurosciences and mental health at the UK’s Medical Research Council (MRC), has been appointed chief scientific officer at a charity performing research in the dementia field.
Beginning mid-August, Dr Latimer will take up the role with the UK Dementia Research Institute (UK DRI), a multimillion-pound investment which is principally funded by MRC. 16 May 2024
Latest In Brief for Sun Pharmaceuticals
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Relevant Ones To Watch News
Massachusetts, USA-based firm VBI Vaccines has initiated a nationwide voluntary recall of PreHevbrio (hepatitis B vaccine), as it proceeds with bankruptcy and the shutdown of its operations. 19 November 2024
12 November 2024
30 October 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze